368 related articles for article (PubMed ID: 32119090)
1. Metabonomics and the Gut Microbiome Associated With Primary Response to Anti-TNF Therapy in Crohn's Disease.
Ding NS; McDonald JAK; Perdones-Montero A; Rees DN; Adegbola SO; Misra R; Hendy P; Penez L; Marchesi JR; Holmes E; Sarafian MH; Hart AL
J Crohns Colitis; 2020 Sep; 14(8):1090-1102. PubMed ID: 32119090
[TBL] [Abstract][Full Text] [Related]
2. Association of Faecal Calprotectin Level and Combined Endoscopic and Radiological Healing in Patients With Crohn's Disease Receiving Anti-tumour Necrosis Factor Therapy.
Noh SM; Oh EH; Park SH; Lee JB; Kim JY; Park JC; Kim J; Ham NS; Hwang SW; Park SH; Yang DH; Byeon JS; Myung SJ; Yang SK; Ye BD
J Crohns Colitis; 2020 Sep; 14(9):1231-1240. PubMed ID: 32157278
[TBL] [Abstract][Full Text] [Related]
3. Early Transmural Response Assessed Using Magnetic Resonance Imaging Could Predict Sustained Clinical Remission and Prevent Bowel Damage in Patients with Crohn's Disease Treated with Anti-Tumour Necrosis Factor Therapy.
Messadeg L; Hordonneau C; Bouguen G; Goutorbe F; Reimund JM; Goutte M; Boucher AL; Scanzi J; Reymond M; Allimant C; Dapoigny M; Pereira B; Bommelaer G; Buisson A
J Crohns Colitis; 2020 Nov; 14(11):1524-1534. PubMed ID: 32533769
[TBL] [Abstract][Full Text] [Related]
4. The gut microbiota and metabolome are associated with diminished COVID-19 vaccine-induced antibody responses in immunosuppressed inflammatory bowel disease patients.
Alexander JL; Mullish BH; Danckert NP; Liu Z; Olbei ML; Saifuddin A; Torkizadeh M; Ibraheim H; Blanco JM; Roberts LA; Bewshea CM; Nice R; Lin S; Prabhudev H; Sands C; Horneffer-van der Sluis V; Lewis M; Sebastian S; Lees CW; Teare JP; Hart A; Goodhand JR; Kennedy NA; Korcsmaros T; Marchesi JR; Ahmad T; Powell N
EBioMedicine; 2023 Feb; 88():104430. PubMed ID: 36634565
[TBL] [Abstract][Full Text] [Related]
5. Metabolic Functions of Gut Microbes Associate With Efficacy of Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases.
Aden K; Rehman A; Waschina S; Pan WH; Walker A; Lucio M; Nunez AM; Bharti R; Zimmerman J; Bethge J; Schulte B; Schulte D; Franke A; Nikolaus S; Schroeder JO; Vandeputte D; Raes J; Szymczak S; Waetzig GH; Zeuner R; Schmitt-Kopplin P; Kaleta C; Schreiber S; Rosenstiel P
Gastroenterology; 2019 Nov; 157(5):1279-1292.e11. PubMed ID: 31326413
[TBL] [Abstract][Full Text] [Related]
6. Influence of Drug Exposure on Vedolizumab-Induced Endoscopic Remission in Anti-Tumour Necrosis Factor [TNF] Naïve and Anti-TNF Exposed IBD Patients.
Verstockt B; Mertens E; Dreesen E; Outtier A; Noman M; Tops S; Schops G; Van Assche G; Vermeire S; Gils A; Ferrante M
J Crohns Colitis; 2020 Mar; 14(3):332-341. PubMed ID: 31504343
[TBL] [Abstract][Full Text] [Related]
7. Baseline Expression of Immune Gene Modules in Blood is Associated With Primary Response to Anti-TNF Therapy in Crohn's Disease Patients.
Bai BYH; Reppell M; Smaoui N; Waring JF; Pivorunas V; Guay H; Lin S; Chanchlani N; Bewshea C; Goodhand JR; Kennedy NA; Ahmad T; Anderson CA;
J Crohns Colitis; 2024 Mar; 18(3):431-445. PubMed ID: 37776235
[TBL] [Abstract][Full Text] [Related]
8. Targeted
Notararigo S; Martín-Pastor M; Viñuela-Roldán JE; Quiroga A; Dominguez-Munoz JE; Barreiro-de Acosta M
J Mol Med (Berl); 2021 Sep; 99(9):1251-1264. PubMed ID: 34021361
[TBL] [Abstract][Full Text] [Related]
9. Bacterial and Fungal Profiles as Markers of Infliximab Drug Response in Inflammatory Bowel Disease.
Ventin-Holmberg R; Eberl A; Saqib S; Korpela K; Virtanen S; Sipponen T; Salonen A; Saavalainen P; Nissilä E
J Crohns Colitis; 2021 Jun; 15(6):1019-1031. PubMed ID: 33300552
[TBL] [Abstract][Full Text] [Related]
10. Anti-TNF Rechallenge After Infliximab Induced Lupus in Crohn's Disease.
Loebenstein M; Schulberg JD
Gastroenterology; 2020 Jun; 158(8):2069-2071. PubMed ID: 31945355
[No Abstract] [Full Text] [Related]
11. Stricturing and Fistulizing Crohn's Disease Is Associated with Anti-tumor Necrosis Factor-Induced Psoriasis in Patients with Inflammatory Bowel Disease.
Weizman AV; Sharma R; Afzal NM; Xu W; Walsh S; Stempak JM; Nguyen GC; Croitoru K; Steinhart AH; Silverberg MS
Dig Dis Sci; 2018 Sep; 63(9):2430-2438. PubMed ID: 29736839
[TBL] [Abstract][Full Text] [Related]
12. Usefulness of monitoring antitumor necrosis factor serum levels during the induction phase in patients with Crohn's disease.
Chaparro M; Guerra I; Iborra M; Cabriada JL; Bujanda L; Taxonera C; García-Sánchez V; Marín-Jiménez I; Barreiro-de Acosta M; Vera I; Martín-Arranz MD; Hernández-Breijo B; Mesonero F; Sempere L; Gomollón F; Hinojosa J; Bermejo F; Beltrán B; Rodríguez Pescador A; Banales JM; Olivares D; Aguilar-Melero P; Menchén L; Ferreiro-Iglesias R; Blazquez Gomez I; Benítez García B; Guijarro LG; Marin A; Bernardo D; Gisbert JP;
Eur J Gastroenterol Hepatol; 2020 May; 32(5):588-596. PubMed ID: 32251204
[TBL] [Abstract][Full Text] [Related]
13. Evolution of cytokines and inflammatory biomarkers during infliximab induction therapy and the impact of inflammatory burden on primary response in patients with Crohn's disease.
Billiet T; Cleynen I; Ballet V; Claes K; Princen F; Singh S; Ferrante M; Van Assche G; Gils A; Vermeire S
Scand J Gastroenterol; 2017 Oct; 52(10):1086-1092. PubMed ID: 28622097
[TBL] [Abstract][Full Text] [Related]
14. Integrated multi-omics reveal gut microbiota-mediated bile acid metabolism alteration regulating immunotherapy responses to anti-α4β7-integrin in Crohn's disease.
Han B; Tang D; Lv X; Fan J; Li S; Zhu H; Zhang J; Xu S; Xu X; Huang Z; Huang Z; Lin G; Zhan L; Lv X
Gut Microbes; 2024; 16(1):2310894. PubMed ID: 38312103
[TBL] [Abstract][Full Text] [Related]
15. The shining DIAMOND for evidence-based treatment strategies for Crohn's disease.
Nakase H; Matsumoto T; Watanabe K; Hisamatsu T
J Gastroenterol; 2020 Sep; 55(9):824-832. PubMed ID: 32661927
[TBL] [Abstract][Full Text] [Related]
16. Understanding anti-TNF treatment failure: does serum triiodothyronine-to-thyroxine (T3/T4) ratio predict therapeutic outcome to anti-TNF therapies in biologic-naïve patients with active luminal Crohn's disease?
Lin S; Chanchlani N; Carbery I; Janjua M; Nice R; McDonald TJ; Bewshea C; Kennedy NA; Ahmad T; Selinger CP; Goodhand JR;
Aliment Pharmacol Ther; 2022 Sep; 56(5):783-793. PubMed ID: 35768996
[TBL] [Abstract][Full Text] [Related]
17. Prospective Evaluation of the Achievement of Mucosal Healing with Anti-TNF-α Therapy in a Paediatric Crohn's Disease Cohort.
Nuti F; Civitelli F; Bloise S; Oliva S; Aloi M; Latorre G; Viola F; Cucchiara S
J Crohns Colitis; 2016 Jan; 10(1):5-12. PubMed ID: 26188350
[TBL] [Abstract][Full Text] [Related]
18. Decreased Enteric Bacterial Composition and Diversity in South American Crohn's Disease Vary With the Choice of Treatment Strategy and Time Since Diagnosis.
Cruz-Lebrón A; D'argenio Garcia L; Talla A; Joussef-Piña S; Quiñones-Mateu ME; Sékaly RP; de Carvalho KIL; Levine AD
J Crohns Colitis; 2020 Jul; 14(6):791-800. PubMed ID: 31758685
[TBL] [Abstract][Full Text] [Related]
19. Spacing the Administration Interval of Anti-TNF Agents: A Valid Strategy for Patients with Inflammatory Bowel Disease?
Torres P; Cañete F; Núñez L; Aguilar A; Mesonero F; Calafat M; Fernández C; Teniente A; Mañosa M; López-Sanromán A; Domènech E
Dig Dis Sci; 2020 Jul; 65(7):2036-2043. PubMed ID: 31858325
[TBL] [Abstract][Full Text] [Related]
20. [Anti-TNF therapy in treatment of luminal Crohn's disease].
Marko B; Prka L
Acta Med Croatica; 2013 Apr; 67(2):179-89. PubMed ID: 24471301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
